The Generalized Anxiety Disorder Scale (GAD-2) is a clinically useful and psychometrically valid tool for screening anxiety symptoms in multiple sclerosis (MS) rehabilitation and neurology care settings, according to a recent study. Importantly, this tool has the potential to identify individuals with MS who are at risk for anxiety disorders and who may benefit from rehabilitation psychology interventions to ultimately improve functioning and quality of life. The sample was comprised of 99 adults (aged 19-72; M=46.2; SD=13.0; 75% female) with a physician-confirmed MS diagnosis who were receiving care in a university-affiliated MS center. Disease durations ranged from 1-37 years (M=10.7; SD=8.4). Participants completed the GAD-7 and GAD-2. Internal consistency was calculated for both measures. Researchers found:
- Internal consistency was excellent for the GAD-7 (Cronbach α=.91) and acceptable for the GAD-2 (α=.77), and the measures were highly correlated (r=.94).
- The GAD-2 had excellent overall accuracy for identifying clinically significant anxiety symptoms.
- A GAD-2 cut-off score of ≥3 provided an optimal balance of good sensitivity (0.87) and excellent specificity (0.92) for detecting clinically significant anxiety symptoms.
- Alternatively, a cut-off score of ≥2 provided excellent sensitivity (1.00) and fair specificity (0.76).
Hughes AJ, Dunn KM, Chaffee T, Bhattarai J, Beier M. Diagnostic and clinical utility of the GAD-2 for screening anxiety symptoms in individuals with multiple sclerosis. [Published online ahead of print June 30, 2018]. Arch Phys Med Rehab. doi:10.1016/j.apmr.2018.05.029.
This Week's Must Reads
Readmission Rates After Thrombectomy for Stroke , J Stroke Cerebrovasc Dis; ePub 2018 Jul 3; Ramchand, et al
Admissions for Psychotic Episodes, Epilepsy Linked , Epilepsia; ePub 2018 Jul 4; Rossi, Kim, et al
Gender and Cognition in Overweight Adults with T2D, Alzheimers Dement; ePub 2018 Jul 4; Espeland, et al
Subjective Improvements in Sleep Apnea Examined, Sleep Med; ePub 2018 Jul 4; Bhat, Gupta, et al
FDA Approves Xeomin for Excessive Drooling, Merz North America news release; 2018 Jul 3
Must Reads in Multiple Sclerosis
Brain Volume Loss as Therapeutic Response Marker , JAMA Neurology; ePub 2018 Jul 2; Andorra, et al
Assessing Environmental Factors and Risk of MS, Mult Scler Relat Disord; ePub 2018 Jun 23; Mowry, et al
Fear of Falling Impacts Leisure-Time Activity in MS, Gait Posture; ePub 2018 Jun 30; Kalron, Aloni, et al
Identifying Anxiety Symptoms in Multiple Sclerosis, Arch Phys Med Rehab; ePub 2018 Jun 30; Hughes, et al
Spinal Cord Volume Loss: Marker of MS Progression, Neurology; ePub 2018 Jun 27; Tsagkas, Magon, et al